Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
Division of Orthopaedic Surgery, McGill University Health Centre, Montreal, Québec, Canada.
BMJ Open. 2021 Feb 26;11(2):e042742. doi: 10.1136/bmjopen-2020-042742.
To determine the proportion of patients with extremity sarcoma who would be willing to participate in a clinical trial in which they would be randomised to one of four different postoperative sarcoma surveillance regimens. Additionally, we assessed patients' perspectives on the burden of cancer care, factors that influence comfort with randomisation and the importance of cancer research.
Prospective, cross-sectional patient survey.
Outpatient sarcoma clinics in Canada, the USA and Spain between May 2017 and April 2020. Survey data were entered into a study-specific database.
Patients with extremity sarcoma who had completed definitive treatment from seven clinics across Canada, the USA and Spain.
The proportion of patients with extremity sarcoma who would be willing to participate in a randomised controlled trial (RCT) that evaluates varying postoperative cancer surveillance regimens.
One hundred thirty complete surveys were obtained. Respondents reported a wide range of burdens related to clinical care and surveillance. The majority of patients (85.5%) responded that they would agree to participate in a cancer surveillance RCT if eligible. The most common reason to participate was that they wanted to help future patients. Those that would decline to participate most commonly reported that participating in research would be too much of a burden for them at a time when they are already feeling overwhelmed. However, most patients agreed that cancer research will help doctors better understand and treat cancer.
These results demonstrate that most participants would be willing to participate in an RCT that evaluates varying postoperative cancer surveillance regimens. Participants' motivation for trial participation included altruistic reasons to help future patients and deterrents to trial participation included the overwhelming burden of a cancer diagnosis. These results will help inform the development of patient-centred RCT protocols in sarcoma surveillance research.
V.
确定愿意参加临床试验的肢体肉瘤患者比例,该试验将患者随机分为四种不同的术后肉瘤监测方案。此外,我们评估了患者对癌症治疗负担的看法、影响随机分组舒适度的因素以及癌症研究的重要性。
前瞻性、横断面患者调查。
2017 年 5 月至 2020 年 4 月期间,加拿大、美国和西班牙的门诊肉瘤诊所。调查数据输入到一个特定的研究数据库中。
已完成加拿大、美国和西班牙七家诊所的肢体肉瘤确定性治疗的患者。
愿意参加评估不同术后癌症监测方案的随机对照试验(RCT)的肢体肉瘤患者比例。
共获得 130 份完整的调查问卷。受访者报告了与临床护理和监测相关的广泛负担。大多数患者(85.5%)表示,如果符合条件,他们愿意参加癌症监测 RCT。参与的主要原因是他们希望帮助未来的患者。那些表示拒绝参与的患者最常表示,在他们已经感到不知所措的时候,参与研究对他们来说负担过重。然而,大多数患者都同意癌症研究将帮助医生更好地了解和治疗癌症。
这些结果表明,大多数参与者愿意参加评估不同术后癌症监测方案的 RCT。参与者参与试验的动机包括帮助未来患者的利他主义原因,而参与试验的障碍包括癌症诊断的压倒性负担。这些结果将有助于为肉瘤监测研究中的以患者为中心的 RCT 方案的制定提供信息。
V。